Home > Journals > Minerva Pneumologica > Past Issues > Minerva Pneumologica 2010 September;49(3) > Minerva Pneumologica 2010 September;49(3):137-41

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions

 

ORIGINAL ARTICLES   

Minerva Pneumologica 2010 September;49(3):137-41

Copyright © 2010 EDIZIONI MINERVA MEDICA

language: English

A 14-year experience with thoracoscopic two windows method for lung cancer

Iwazaki M., Inoue H.

Division of General Thoracic Surgery, Department of Surgery, Tokai University School of Medicine, Isehara, Kanagawa, Japan


PDF


Aim. It has been 14 years since the thoracoscopic two windows method was developed. In this study we assessed 100 cases of stage IA lung cancer cases in which 5 years or more had passed since the procedure was performed.
Methods. Surgery was performed by making small skin incisions in the 4th or 5th intercostal space at 2 sites centered on the inferior angle of the scapula. For right thoracotomy the posterior incision was made 2 cm long, and the anterior incision was 1 cm long, and for left thoracotomy the anterior incision was made 2 cm long, and the posterior incision was 1 cm long. Pulmonary lobectomy and mediastinal lymph node dissection by the thoracoscopic two windows method was performed in consecutive 100 cases of lung cancer with a preoperative or postoperative pathological diagnosis of stage IA, T1N0M0, and perioperative factors were assessed in comparison with 92 cases with a preoperative or postoperative pathological diagnosis of stage IA, T1N0M0 lung cancer in which standard thoracotomy was performed during the same period.
Results. Mean operation time was 2 hours 35 minutes, and mean blood loss was 45.6 mL. The mean number of lymph nodes removed by mediastinal lymph node dissection was 28, and the 5-year survival rate was 78.7% in the standard thoracotomy group and 94.6% in the thoracoscopic surgery group.
Conclusion. Thoracoscopic two windows method is capable of serving as a standard surgical procedure for stage IA lung cancer.

top of page